August 2011
Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p5
Trade Publication
The article discusses a collaboration between pharmaceutical firms Evotec AG and UCB to treat central nervous system (CNS) disorders. In August 2011, the two entered a three year agreement to identify small molecule modulators of priority biological targets which UCB selected. Evotec will use their integrated drug discovery expertise to target these molecules, receiving a fixed fee during the period, as well as royalties on net sales from any drugs developed during the collaboration.


Related Articles

  • COMPANY SPOTLIGHT - UCB.  // PharmaWatch: Monthly Review;Nov2009, Vol. 8 Issue 11, p60 

    The article profiles the biopharmaceutical company UCB SA in Belgium. Accordingly, the company is engaged in the research, development, and commercialization of pharmaceutical drugs for treating central nervous system (CNS) and immunology disorders. It operates to more than 40 countries...

  • Evotec enters into integrated drug discovery collaboration with UCB.  // PharmaWatch: CNS;Aug2011, Vol. 10 Issue 8, p19 

    The article announces that Evotec AG has entered into a three year integrated discovery collaboration with UCB SA to identify molecule moderators of priority biological targets involved in central nervous system (CNS) disorders.

  • Drug Delivery Across the Blood-Brain Barrier. Y. Chen; Dalwadi, G.; Benson, H.A.E. // Current Drug Delivery;Dec2004, Vol. 1 Issue 4, p361 

    The brain is protected and isolated from the general circulation by a highly efficient blood-brain barrier. This is characterised by relatively impermeable endothelial cells with tight junctions, enzymatic activity and active efflux transport systems. Consequently the blood-brain barrier is...

  • Cannabinoids courting attention because of their potential in CNS disorders.  // Drugs & Therapy Perspectives;Feb2004, Vol. 20 Issue 2, p19 

    Cannabis has been used medicinally for thousands of years, despite mainly anecdotal reports of its efficacy. Recently, endogenous cannabinoids have been identified and synthetic analogues produced. Animal models and preliminary human studies suggest that cannabinoids may have therapeutic utility...

  • Pethidine overdose.  // Reactions Weekly;4/21/2007, Issue 1148, p28 

    The article presents a case study of a 17-year-old girl who developed central nervous system (CNS) disorders after ingesting an overdose of pethidine. The girl, who was found in an unconscious state, received naloxone at the hospital. She received another dose of naloxone without any improvement...

  • UCB Dumps 50+ Programs in $667M Deal with GSK.  // BioWorld International;1/28/2009, Vol. 14 Issue 4, p6 

    This article reports on the move of UCB SA to divest its smaller operations in 2009. UCB reached a deal to sell more than 50 such programs to GlaxoSmithKline PLC. The deal includes UCB operations in the Far East, Middle East, Latin America and Africa. The move by UCB is part of its SHAPE...

  • Boehringer Ingelheim to collaborate on CNS drugs.  // PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p13 

    This article reports that pharmaceutical firms, Evotec OAI AG and Evotec Neurosciences GmbH, have entered into a three-year research collaboration with pharmaceuticals giant Boehringer Ingelheim to develop small molecule therapeutics for diseases of the central nervous system. Under the terms of...

  • Diseases of the central nervous system. Hood, N.A. // British Medical Journal;11/15/1975, Vol. 4 Issue 5993, p398 

    Evaluates the diseases of the central nervous system. Enumeration of disorders and diseases; Classification of treatments; Division of diseases according to effects.

  • Diseases of the central nervous system. Parkes, J.D. // British Medical Journal;10/11/1975, Vol. 4 Issue 5988, p90 

    Focuses on the diseases of the central nervous system. Enumeration of the diseases; Discussion on the causes of each disease entity; Treatment of choice for each disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics